{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:27:39Z","timestamp":1787243259923,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.colsurfb.2022.112785","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T23:17:49Z","timestamp":1661296669000},"page":"112785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Comparative analysis of PEG-liposomes and RBCs-derived nanovesicles for anti-tumor therapy"],"prefix":"10.1016","volume":"218","author":[{"given":"Supriya","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Dumoga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetu","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.colsurfb.2022.112785_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.colsurfb.2022.112785_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nano.2012.05.013","article-title":"The big picture on nanomedicine: the state of investigational and approved nanomedicine products","volume":"9","author":"Etheridge","year":"2013","journal-title":"Nanomedicine"},{"issue":"25","key":"10.1016\/j.colsurfb.2022.112785_bib3","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1056\/NEJMra0912273","article-title":"Nanomedicine","volume":"363","author":"Kim","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.colsurfb.2022.112785_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.colsurfb.2022.112785_bib5","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/nbt1006-1211","article-title":"The emerging nanomedicine landscape","volume":"24","author":"Wagner","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.colsurfb.2022.112785_bib6","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.2147\/IJN.S46900","article-title":"Nanopharmaceuticals (part 1): products on the market","volume":"9","author":"Weissig","year":"2014","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.colsurfb.2022.112785_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.colsurfb.2022.112785_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1081\/CNV-100103136","article-title":"Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy","volume":"19","author":"Gabizon","year":"2001","journal-title":"Cancer Investig."},{"issue":"38","key":"10.1016\/j.colsurfb.2022.112785_bib9","doi-asserted-by":"crossref","first-page":"14265","DOI":"10.1073\/pnas.0805135105","article-title":"Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts","volume":"105","author":"Lundqvist","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.colsurfb.2022.112785_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","article-title":"Nanoparticle uptake: the phagocyte problem","volume":"10","author":"Gustafson","year":"2015","journal-title":"Nano Today"},{"key":"10.1016\/j.colsurfb.2022.112785_bib11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control Release"},{"issue":"3","key":"10.1016\/j.colsurfb.2022.112785_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3\u20134","key":"10.1016\/j.colsurfb.2022.112785_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0927-7765(99)00156-3","article-title":"'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption","volume":"18","author":"Gref","year":"2000","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"2\u20133","key":"10.1016\/j.colsurfb.2022.112785_bib14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"issue":"12","key":"10.1016\/j.colsurfb.2022.112785_bib15","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.drudis.2014.08.015","article-title":"Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics","volume":"19","author":"Verhoef","year":"2014","journal-title":"Drug Discov. Today"},{"issue":"9","key":"10.1016\/j.colsurfb.2022.112785_bib16","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","article-title":"Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions","volume":"14","author":"Chanan-Khan","year":"2003","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.colsurfb.2022.112785_bib17","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.addr.2011.06.017","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.colsurfb.2022.112785_bib18","first-page":"37","article-title":"Repeated injections of PEG-PE liposomes generate anti-PEG antibodies","volume":"10","author":"Sroda","year":"2005","journal-title":"Cell Mol. Biol. Lett."},{"key":"10.1016\/j.colsurfb.2022.112785_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"Pt B","key":"10.1016\/j.colsurfb.2022.112785_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J. Control Release"},{"issue":"Pt B","key":"10.1016\/j.colsurfb.2022.112785_bib21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jconrel.2015.07.019","article-title":"Cell membrane-camouflaged nanoparticles for drug delivery","volume":"220","author":"Luk","year":"2015","journal-title":"J. Control Release"},{"key":"10.1016\/j.colsurfb.2022.112785_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.biomaterials.2017.02.041","article-title":"Cell membrane-derived nanomaterials for biomedical applications","volume":"128","author":"Fang","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.colsurfb.2022.112785_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1776","article-title":"Red blood cells membrane-derived nanoparticles: applications and key challenges in their clinical translation","author":"Malhotra","year":"2022","journal-title":"Wiley Inter. Rev. Nanomed. Nanobiotechnol."},{"issue":"9","key":"10.1016\/j.colsurfb.2022.112785_bib24","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/j.1537-2995.2005.00564.x","article-title":"The application of a new quantitative assay for the monitoring of integrin-associated protein CD47 on red blood cells during storage and comparison with the expression of CD47 and phosphatidylserine with flow cytometry","volume":"45","author":"Stewart","year":"2005","journal-title":"Transfusion"},{"issue":"5A","key":"10.1016\/j.colsurfb.2022.112785_bib25","first-page":"3599","article-title":"Nanoerythrosomes, a new derivative of erythrocyte ghost: III. Is phagocytosis involved in the mechanism of action?","volume":"17","author":"Lejeune","year":"1997","journal-title":"Anticancer Res."},{"issue":"27","key":"10.1016\/j.colsurfb.2022.112785_bib26","doi-asserted-by":"crossref","first-page":"10980","DOI":"10.1073\/pnas.1106634108","article-title":"Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform","volume":"108","author":"Hu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.colsurfb.2022.112785_bib27","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1039\/C3NR06371B","article-title":"Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles","volume":"6","author":"Luk","year":"2014","journal-title":"Nanoscale"},{"issue":"3","key":"10.1016\/j.colsurfb.2022.112785_bib28","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7150\/thno.17259","article-title":"Enhanced blood suspensibility and laser-activated tumor-specific drug release of theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes","volume":"7","author":"Su","year":"2017","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.colsurfb.2022.112785_bib29","doi-asserted-by":"crossref","first-page":"10414","DOI":"10.1021\/nn503779d","article-title":"Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy","volume":"8","author":"Piao","year":"2014","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.colsurfb.2022.112785_bib30","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/ja2084338","article-title":"Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake","volume":"134","author":"Walkey","year":"2012","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.colsurfb.2022.112785_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1021\/acs.langmuir.5b03014","article-title":"Colloidal properties of nanoerythrosomes derived from bovine red blood cells","volume":"32","author":"Kuo","year":"2016","journal-title":"Langmuir"},{"key":"10.1016\/j.colsurfb.2022.112785_bib32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.actbio.2020.11.049","article-title":"Polymeric micelles coated with hybrid nanovesicles enhance the therapeutic potential of the reversible topoisomerase inhibitor camptothecin in a mouse model","volume":"121","author":"Malhotra","year":"2021","journal-title":"Acta Biomater."},{"issue":"25","key":"10.1016\/j.colsurfb.2022.112785_bib33","doi-asserted-by":"crossref","first-page":"22141","DOI":"10.1021\/acsami.9b04827","article-title":"Red blood cells-derived vesicles for delivery of lipophilic drug camptothecin","volume":"11","author":"Malhotra","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"2","key":"10.1016\/j.colsurfb.2022.112785_bib34","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsabm.1c01070","article-title":"Engineering cellular membrane for dual mode therapy using NIR responsive photosensitizer and reversible topoisomerase inhibition activity","volume":"5","author":"Malhotra","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"issue":"3","key":"10.1016\/j.colsurfb.2022.112785_bib35","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/157016311796798991","article-title":"Passive and active tumour targeting with nanocarriers","volume":"8","author":"Hirsjarvi","year":"2011","journal-title":"Curr. Drug Discov. Technol."}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776522004684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776522004684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:21:30Z","timestamp":1760527290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776522004684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":35,"alternative-id":["S0927776522004684"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2022.112785","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative analysis of PEG-liposomes and RBCs-derived nanovesicles for anti-tumor therapy","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2022.112785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112785"}}